Maze Therapeutics (NASDAQ:MAZE) Insider Atul Dandekar Sells 3,243 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 3,243 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total transaction of $84,350.43. Following the transaction, the insider directly owned 32,316 shares of the company’s stock, valued at $840,539.16. This represents a 9.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Atul Dandekar also recently made the following trade(s):

• On Wednesday, September 2nd, Atul Dandekar sold 3,191 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.47, for a total transaction of $84,465.77.
• On Friday, August 28th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.58, for a total value of $206,850.00.
• On Wednesday, July 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.34, for a total value of $205,050.00.
• On Monday, June 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $28.02, for a total transaction of $210,150.00.

Maze Therapeutics Trading Up 1.3%

MAZE stock opened at $26.21 on Friday. Maze Therapeutics, Inc. has a 52-week low of $14.27 and a 52-week high of $53.65. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. The firm has a market cap of $1.46 billion, a P/E ratio of -10.40 and a beta of 2.17. The company’s 50-day simple moving average is $28.69 and its 200-day simple moving average is $31.17.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting the consensus estimate of ($0.76). As a group, equities analysts forecast that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Maze Therapeutics

A number of hedge funds have recently made changes to their positions in MAZE. California State Teachers Retirement System lifted its position in shares of Maze Therapeutics by 54,096.5% in the second quarter. California State Teachers Retirement System now owns 777,720 shares of the company’s stock valued at $23,207,000 after acquiring an additional 776,285 shares in the last quarter. Frazier Life Sciences Management L.P. increased its position in shares of Maze Therapeutics by 10.2% during the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after purchasing an additional 465,641 shares in the last quarter. AXQ Capital LP raised its stake in Maze Therapeutics by 114.1% in the 2nd quarter. AXQ Capital LP now owns 15,193 shares of the company’s stock valued at $453,000 after purchasing an additional 8,098 shares during the last quarter. Braidwell LP acquired a new position in Maze Therapeutics in the 2nd quarter valued at $34,019,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Maze Therapeutics by 4,054.3% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,739 shares of the company’s stock valued at $529,000 after purchasing an additional 17,312 shares in the last quarter.

Maze Therapeutics News Roundup

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on MAZE shares. BTIG Research reissued a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Finally, Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Maze Therapeutics currently has an average rating of “Buy” and a consensus price target of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.